Symbol="EDIT"
AssetType="Common Stock"
Name="Editas Medicine Inc"
Description="Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts."
CIK="1650664"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="11 HURLEY ST., CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="729655000"
EBITDA="-219838000"
PERatio="None"
PEGRatio="0"
BookValue="4.738"
DividendPerShare="0"
DividendYield="0"
EPS="-3.02"
RevenuePerShareTTM="0.331"
ProfitMargin="0"
OperatingMarginTTM="-9.92"
ReturnOnAssetsTTM="-0.26"
ReturnOnEquityTTM="-0.527"
RevenueTTM="22792000"
GrossProfitTTM="-155246000"
DilutedEPSTTM="-3.02"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.455"
AnalystTargetPrice="13.41"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="26.38"
PriceToBookRatio="1.718"
EVToRevenue="12.25"
EVToEBITDA="-1.587"
Beta="1.801"
num_52WeekHigh="19.97"
num_52WeekLow="6.33"
num_50DayMovingAverage="9.18"
num_200DayMovingAverage="9.56"
SharesOutstanding="81526000"
DividendDate="None"
ExDividendDate="None"
symbol="EDIT"
open="8.95"
high="9.00"
low="8.50"
price="8.61"
volume="1143479.00"
latest_trading_day="2023-07-14"
previous_close="8.95"
change="-0.34"
change_percent="-3.7989%"
aroon_positive_momentum_days="59"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="59"
Volume_recent_avg="2027796"
Change_recent_avg="-0.02"
Delta_recent_avg="0.55"
Variance_recent_avg="0.28"
Change_ratio_recent_avg="-0.32"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="59"
Aroon_momentum_negative="41"
image_negative_thumbnail_id_1="1117"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0150.jpeg"
image_negative_thumbnail_id_2="134"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_neutral_thumbnail_id_1="549"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_neutral_thumbnail_id_2="587"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_positive_thumbnail_id_1="650"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0058.jpeg"
image_positive_thumbnail_id_2="616"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0092.jpeg"
image_professor_thumbnail_id_1="1202"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
